Rapid Colorimetric Assay for Salivary Detection of Sars-CoV-2

The global pandemic of SARS-CoV-2 has created unprecedented challenges for public health systems, necessitating innovative solutions for timely and accurate virus detection. Despite a decreasing trend in new cases by early 2024, the persistent presence of millions of confirmed cases and deaths emphasizes the need for effective containment strategies. Conventional diagnostic methods, like RT-PCR and serological assays, have limitations in invasiveness, turnaround time, and scalability. In response, we've developed a rapid and non-invasive approach for detecting SARS-CoV-2 in saliva samples. Using gold nanoparticles, our method coats the virus densely, enabling precise identification. This biosensor technique shows efficacy in real-world samples, offering rapid and reliable detection within a short timeframe. It's versatile, extending beyond SARS-CoV-2 to other viruses, broadening its applicability. Saliva-based diagnostics reduce the need for invasive procedures, enhancing patient acceptance. Our biosensor technology is scalable and cost-effective, addressing healthcare disparities. However, refining sensitivity and specificity across different saliva samples, considering virus genetic variations and biological interferences, is crucial. In conclusion, our study marks a significant advancement in COVID-19 diagnostics, providing a transformative solution for rapid and non-invasive virus detection. Early identification and intervention are facilitated, promising to bolster pandemic management efforts and global preparedness against emerging threats. Collaborative efforts and strategic dissemination are essential for equitable access and adoption across diverse healthcare settings.